EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

7:00am - 8:00am 60 mins
Continental Breakfast
7:00am - 5:00pm 600 mins
Registration Open
8:00am - 8:55am 55 mins
The year of RNA and the start of a new era
  • Moderator Mani Foroohar - Managing Director, Senior Research Analyst, Leerink Partners
  • Panelist Robert Habib - CEO, MiNA Therapeutics
  • Panelist Sean Marett - CBO and CCO, BioNTech
  • Panelist Romesh Subramanian - Entrepreneur-in-Residence, Atlas Venture

The range of RNA therapeutic modalities has expanded significantly since the first-mover companies such as Alnylam, Ionis and Santaris appeared on the global stage. Today, the industry has propelled a variety of novel approaches into the clinic such as small activating RNAs, microRNAs and has been able to leverage mRNAs to develop uniquely personalized medicine for each individual patient. Many of initial hurdles in delivery or efficacy have also been addressed making it possible to realize the full potential of RNA therapies. What will 2019 bring?

8:00am - 8:55am 55 mins
Rare and orphan diseases: The biotech industry poised to make a dent in treatment and diagnosis
  • Moderator Ted Tenthoff - Analyst, Piper Jaffray & Co.

There are an estimated 7,000+ rare and orphan diseases, and today there are therapies for about 600 rare diseases. With regulatory benefits of the orphan drug act, new technologies including gene and cell therapy and gene editing, market exclusivity and pricing advantages, many biotech companies and big pharma are focusing on orphan diseases. But some counter that premium pricing will break the US healthcare system and are limiting access to care. What is the cost of life extension or even potentially a cure for a debilitating, life-threatening disease?

8:00am - 5:00pm 540 mins
One-to-one meetings
8:30am - 12:00pm 210 mins
Company Presentations
12:00pm - 1:45pm 105 mins
Lunch Plenary: At the intersection of policy and sentiment: Its impact on the industry – the good and bad driving us forward.
  • Moderator Wade Ackerman - Partner, Covington & Burling LLP
  • Panelist Rachel King - CEO, GlycoMimetics, Inc.
  • Panelist Jonathan S. Leff - Partner and Chairman, Deerfield Management and Deerfield Institute
  • Panelist Joe Panetta - President and CEO, Biocom
  • Panelist Lauren Silvis - Chief of Staff to FDA Commissioner Scott Gottlieb, FDA

The biotechnology and healthcare sector is being buffeted by a multitude of forces, including public sentiment around issues like drug pricing. Policymakers are as active as ever, addressing issues like the opioid epidemic, emerging technologies, the rapid integration of digital technologies with medicine, and the overall cost of healthcare. Add to the mix a public and private market whose enthusiasm for this sector has been at an all-time high for a sustained period of time. This panel will discuss the key public policy issues affecting the industry and address the question of how this sector will evolve.

1:45pm - 5:00pm 195 mins
Company Presentations
2:00pm - 2:55pm 55 mins
Early seed alternative financing
  • Moderator Ben Johnson - Managing Director, Head, National Early Stage Life Science, SVB Silicon Valley Bank
  • Panelist Grace E. Colón - President and CEO, InCarda Therapeutics Inc
  • Panelist Natalie Dakers - President and CEO, Accel-Rx
  • Panelist Hakan Goker - Senior Investment Director, M-Ventures
  • Panelist Lesley Stolz - Head, JLABS CA, Johnson and Johnson Innovation, JLABS
4:30pm - 5:15pm 45 mins
STAT Roundup
  • Panelist Adam Feuerstein - Senior Writer, STAT
  • Panelist Damian Garde - National Biotech Reporter, STAT
  • Panelist Rebecca Robbins - San Francisco Correspondent, STAT
5:15pm - 6:15pm 60 mins
Closing reception
Showing of Streams
5:15pm - 6:15pm

Closing reception